Sarcomas are rare tumors that develop in connective tissues, with approximately 3000 new cases per year in France. There are many types of sarcomas, among which 15% are liposarcomas. The latter are characterized by a genetic anomaly corresponding to the amplification of the MDM2 gene. Observed in almost 100% of cases, this makes it a preferred therapeutic target. Currently, there is no effective treatment to combat liposarcomas, and their diagnosis is lengthy and difficult. A better understanding of the role of the MDM2 protein is a major challenge to improve our understanding of the development of liposarcomas. In our team, we have identified that the activity of MDM2 in liposarcomas is linked to amino acid metabolism. Our work involves exploring in detail this new metabolic role of MDM2 and identifying factors playing an important role in their occurrence. Our goals are to improve the understanding of the development of this tumor and to evaluate the development of new diagnostic and therapeutic strategies to combat liposarcomas.
The long-term objective of our work is to extend the study of metabolism to other types of sarcomas.
Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).
U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)
Institut de Recherche en Cancérologie de